

Product Management Service (PMS) – Frequently Asked Questions (FAQs)

2 June 2025

Disclaimer

This document contains a direct record of frequently asked questions (FAQs) through Slido.com during the Product Management Service (PMS) events over past months, complementing them. The FAQs are split per topic.

Nothing in this document should be taken as an explicit commitment on behalf of the EMA, or the PMS product team. The responses represent the expert view of the Product team and are not official statements by the European Medicines Agency nor its partners.

For convenience, many technical terms are explained in the table of abbreviations at the beginning of this document.

For general inquiries, please contact the PMS team via the EMA Service Desk. For questions or comments around the content of this FAQ document, please raise a ticket via the EMA Service Desk.

Contents

1. Access and registration	5
1.1. Can I access PMS PUI or PMS API with the same user and password as for RMS, OMS and SMS?5	
1.2. If a user has already an IRIS / eAF Industry Admin or IRIS / eAF Competent Authority Admin role, will the user automatically become IRIS PLM admin?	5
1.3. Are IRIS / PLM Industry Admin and IRIS / PLM NCA Admin roles sufficient to access PMS?	5
1.4. Is there a specific requirement to request the Industry user role or Industry qualified user role?5	
1.5. What is the difference between NCA user role and NCA qualified user role?.....	5
1.6. How is it possible to verify who is the IRIS/PLM Industry Admin for a Company if it already exists?	6
1.7. If I need to access products data in PMS on behalf of more than one ORG ID, shall I submit separate requests in IAM?	6
1.8. How can software vendors get access to PMS API?	6
1.9. Is PMS API publicly available to read product data?.....	6
2. Data model	6
2.1. When will PMS database contain all PMS data fields reported in EU IG Chapter 2?.....	6
2.2. When will the updated version of EU IG Chapter 2 be released?	6
2.3. Will the 'PMS' section in the SPOR portal be updated?	6
2.4. Are MAHs required to check their authorised product data in PMS as result of the XEVMPD data load?	7
2.5. How is the Master File Location (MFL) created in PMS?	7
2.6. An authorised medicinal product can have more than one packaged medicinal product, each of them can have a different authorisation status. How is this managed in PMS?	7
2.7. Will the entire PMS product dataset be compulsory to be completed?	7
2.8. Is PMS designed to store only Authorised Medicinal Products (AMP) or also for Investigational Medicinal Products (IMP)?	8
2.9. Will the Pharmaceutical Product Identifier (PhPID) be integrated in PMS?	8
2.10. Where can I find the MPID assigned to my product and the PCID linked to my packaged medicinal product?	8
2.11. The Data Carrier Identifier is a data element mentioned in the EU IG Chapter 2. Will PMS users be required to provide and maintain Global Trade Item Number (GTIN) in the PMS?.....	8
2.12. How can product data from PMS be exported and in which formats?.....	9
2.13. Free text fields coming from XEVMPD show the information in capital letters, why?	9
2.14. In PMS there are different sections for ingredients. Where is this data coming from?.....	9
2.15. I have submitted an update to XEVMPD and a new PMS ID has been generated in PMS for my product. Why is this happening?	9
2.16. Different EV Codes have been migrated under the same medicinal product in PMS. Nevertheless, they should not be grouped as they are considered different marketing authorisation even though all the data in XEVMPD is the same. They are just duplicate marketing authorisations. How can I split the products in PMS?	10
3. Product User Interface (PUI).....	10
3.1. How often the product data between XEVMPD and PMS PUI is synchronised?	10
3.2. Are Product EV Codes (PRD) made available PMS PUI?	10
3.3. A medicinal product or packaged medicinal product does not have an EV code associated. What is happening?	10
3.4. Why some PMS data elements are empty and what is the impact of this?	11
3.5. In PMS PUI the Marketing status and marketing status dates are visible. From which system does this information come from?	11

3.6. Will the Marketing status captured in IRIS be synced with PMS PUI in real-time?	11
3.7. Is there a way to export all product data?.....	12
3.8. Will centrally authorised products with authorisation country NO, IS and LI disappear from the Product UI?	12
3.9. Why some medicinal products don't have an MA number?	12
3.10. The MedDRA version of XEVMPD and the Product UI don't match. Why?	12
3.11. During the enrichment process, who has access to the different change requests created?....	13
4. Known issues in PMS	13
4.1. After reviewing my products in the PMS API or the Product UI I have found several issues with my data. What should I do in order to correct it?	13
4.2 Taking into account the known issues, how should I manage the verification of data in PMS? ...	18
5. Submission of data to support ESMP.....	18
5.1. What is the deadline for the enrichment of data in PMS?.....	18
5.2. Is it possible for PMS PUI users to create pack sizes directly in the PUI or the PMS API instead of in XEVMPD?.....	18
5.3. What information should be included in the package description in XEVMPD?	19
5.4. Does the content of the PMS package description match with the XEVMPD package description?	20
5.5. The user is requested to specify the pack size of authorised medicinal products in the package description field available in XEVMPD. Will the free text reported in XEVMPD be transformed in structured data in PMS?	20
5.6. Do I need to submit all authorised pack sizes for all my products, or shall I do it only for those products that fall under the ULCM (Union List of Critical Medicines)?.....	20
5.7. When submitting the manufacturers and manufacturing business operations as part of the enrichment process, which manufacturers should be included?	21
5.8. Manufacturing business operation for CAPs are not captured as in the eAF. Why?	21
5.9. When inserting a new pack size in XEVMPD, instead of a new packaged medicinal product, a new medicinal product is created in PMS. Why is this happening?	21
6. PMS and the web-based electronic Application Form (eAF)	21
6.1. eAF retrieves authorised product data from PMS. What is the impact on the use of eAF when products data are not up-to-date in XEVMPD?.....	21
6.2. I want to use the web-based eAF for products that are not in scope of XEVMPD, such as herbal or homeopathic products. What shall I do?	22
6.3. For MRPs and DCPs, after a medicinal product is authorised in the Referenced Member State but while it is under the national phase on the Concerned Member States, a variation might need to be submitted. How and by when these pending products can be submitted to XEVMPD so they appear in the PLM Portal?	22
7. Guidance & Support.....	23
7.1. How shall any identified PMS related data quality issue or questions be reported?	23
7.2. Where are all PMS guidance documents stored?	24
7.3. Where can users find regular news on PMS work?	24

Acronym key and glossary terms

API	Application Programming Interface
CAP	Centrally Authorised Product
eAF	Electronic Application Form
EMA	European Medicines Agency
ESMP	European Shortage Monitoring Platform
EU IG	EU IDMP Implementation Guide
GTIN	Global Trade Item Number
IAM	EMA Account Management system
MAH	Marketing Authorisation Holder
MFL	Master File Location
MPID	Medicinal Product Identifier
NCA	National Competent Authority
Non-CAP	Non – Centrally Authorised Product
OMS	Organisation Management Service
ORG-ID	Organisation Identifier
PhPID	Pharmaceutical Medicinal Product Identifier
PCID	Packaged Medicinal Product Identifier
PLM	Product Lifecycle Management
PMS	Product Management System
PSMF	Pharmacovigilance System Master File
PUI	Product User Interface
Q&A	Question and Answer
QPPV	Qualified Pharmacovigilance Person
RMS	Referentials Management Service
SMS	Substance Management Service
SPOR	Substance, Product, Organisation, Referentials
XEVMPD	eXtended EudraVigilance Medicinal Product Dictionary
XEVPRM	eXtended EudraVigilance Medicinal Product Report Message

1. Access and registration

1.1. Can I access PMS PUI or PMS API with the same user and password as for RMS, OMS and SMS?

To access the systems, you need to request a dedicated PMS PUI or API role, either as a regular user or a qualified user from the industry/NCA. The RMS, OMS and SMS roles, such as super users, are not linked to PMS, so a separate request is necessary.

For more information, please visit the PLM page and click on the PMS guidance section. In particular, please refer to:

- [On-boarding of users to Substance, Product, Organisation and Referentials \(SPOR\) data services](#);
- [EU IG chapter 1](#) for the registration process.

Although you need a different role type, your user credentials and password can remain the same if you choose to update them in your [EMA Account Management platform](#) (IAM).

1.2. If a user has already an IRIS / eAF Industry Admin or IRIS / eAF Competent Authority Admin role, will the user automatically become IRIS PLM admin?

Please be aware that, in agreement with eAF and ePI team, a name change was applied from "IRIS EAF Industry Admin" and "IRIS EAF Competent Authority Admin" to "IRIS / PLM Industry Admin" or "IRIS / PLM NCA Admin."

This change affects both categories, merging the roles to encompass all products hosted in the PLM portal. Consequently, if you hold roles in eAF and ePI, all privileges are merged.

If user role was granted before the PMS PUI go-live on 31 May 2024, the user will simply see the role name update.

For further information please refer to slides 12 and 13 of the [Product Management Service \(PMS\) Product UI training \(access & navigation\)](#) (3 June 2024) session.

1.3. Are IRIS / PLM Industry Admin and IRIS / PLM NCA Admin roles sufficient to access PMS?

No, to access PMS PUI and/or API there are additional steps the user should follow. Please refer to **section 3. PMS Registration requirements** of the [EU IG chapter 1](#).

1.4. Is there a specific requirement to request the Industry user role or Industry qualified user role?

As explained in [EU IG Chapter 5](#) and [Annex A](#), Industry users can request one of the two roles available (regular user or qualified user role) based on the type of access they are looking for. The **qualified user role** provides full access to the entire product data set (public and confidential data) of the authorised medicinal products under their organisation, while the **regular user role** has limited access to product data (only public), based on the requirements mentioned in Annex A to EU IG Chapter 5.

1.5. What is the difference between NCA user role and NCA qualified user role?

There is no difference between the NCA regular user and NCA qualified user roles in terms of accessibility of product data (full data set of authorised medicinal products is accessible with both roles). The distinction between these roles is at the level of the **edit functionality**: only granted to the

qualified user role. However, this role is not yet available for NCA users. The Agency will announce in due time when this last role can be requested.

1.6. How is it possible to verify who is the IRIS/PLM Industry Admin for a Company if it already exists?

It is good practice that each Organisation has at least two IRIS/PLM Admin user and these are known internally. In case this is unknown, please submit a request to EMA service desk.

1.7. If I need to access products data in PMS on behalf of more than one ORG ID, shall I submit separate requests in IAM?

No, as announced at the [SPOR status update](#) webinar on 10 April 2024, users can submit in a single request multiple ORG IDs access in IAM.

When requesting access to EMA services, users can add organisations to a shopping cart and keep searching for other organisations with different criteria.

1.8. How can software vendors get access to PMS API?

Software vendors can access Marketing Authorisation Holder's product data through PMS API by using the API secret credential assigned to the relevant IRIS/PLM Admin user of a specific organisation.

1.9. Is PMS API publicly available to read product data?

No, at the moment, PMS API is only accessible upon registration to EMA Account Management portal. User can select the most applicable user role type as mentioned in [EU IG Chapter 1](#).

Moreover, the Agency is working to develop a public PMS API whose release will be communicated in due time.

Currently, a public report of medicinal products is accessible through the [Product Lifecycle Management \(PLM\) portal](#).

2. Data model

2.1. When will PMS database contain all PMS data fields reported in EU IG Chapter 2?

The implementation of all PMS data elements as reported in [EU IG chapter 2](#) will occur. During the initial migration of data to PMS, only the information from SIAMED and XEVMPD was captured. As the PMS data model is bigger than the data model from SIAMED or XEVMPD, not all fields mentioned in Chapter 2 of the EU IG are filled.

These missing data will be enriched by MAHs over time and based on priorities. The Agency will notify the users with sufficient time so they can gather this information and be ready to submit it to PMS.

2.2. When will the updated version of EU IG Chapter 2 be released?

The latest version of the [European Union IDMP Implementation Guide \(EU IG\) Chapter 2](#) was released on May 2025. No major updates are foreseen in the near future.

2.3. Will the 'PMS' section in the SPOR portal be updated?

Access to PMS is hosted under the [PLM portal](#) only. This is due to the connections with other databases such as the eAF and ePI portals.

2.4. Are MAHs required to check their authorised product data in PMS as result of the XEVMPD data load?

Yes, upon registration being completed, MAHs are recommended to check their authorised product data in PMS through API and/or PUI. It is in MAH's interest to ensure the accuracy of their products data.

Please review the known issues section of this document to make sure you do not create tickets for issues that are already known and being worked on.

For further information on how to access and navigate through PMS API and PUI, please refer to the following training sessions and Q&A clinic sessions:

- [Informative webinar on PMS Product User Interface usage and key actions for Marketing Authorisation Holders \(with demo\)](#) on 29 October 2024;
- [Training webinar on Product Management Service \(PMS\) Product User Interface \(PUI\)](#) hosted on 16 October 2024;
- [Product Management Service \(PMS\) Application Programming Interface \(API\) training session](#) hosted on 8 July 2024;
- [Product Management Service \(PMS\) Product UI training \(access & navigation\)](#) hosted on 3 June 2024;
- Series of Q&A clinic on Product Management Service (PMS) hosted since the PMS Go-Live and available at this [Link](#).

2.5. How is the Master File Location (MFL) created in PMS?

As stated in the [EU IG Chapter 2](#), Master File Location (MFL) is currently created and maintained in XEVMPD and loaded into PMS as per migration rules reported in [EU IG Chapter 7](#).

For the time being, PSMFL should be created and maintained following the rules stated in [Chapter 3.II of XEVMPD](#). If, during the lifecycle of the product, changes on the PSMFL are submitted to XEVMPD, these updates will also be reflected in PMS following the deltas explained in [EU IG Chapter 9](#).

2.6. An authorised medicinal product can have more than one packaged medicinal product, each of them can have a different authorisation status. How is this managed in PMS?

As stated in sections Authorisation status available at both medicinal and packaged medicinal product level in [EU IG Chapter 2](#), in case of different authorisation statuses for different packaged medicinal products of the same authorised medicinal product the following rules applies:

- If all the packages have the same authorisation status, the applicable authorisation status value will be reflected at product level.
- If different values apply to the different packages, then, the following priority list should be used. That means that the first term in this list used in any package will define the authorisation status at product level.

Valid > Valid Transferred > Valid Renewed > Valid after lifting of suspension > Suspended > Expired due to Sunset Clause > Expired > Withdrawn > Not renewed > Revoked

2.7. Will the entire PMS product dataset be compulsory to be completed?

It depends by the PMS business rules mentioned in [EU IG Chapter 2](#). For each of the classes of attributes a specific set of rules such as the conformance type has been defined. This information is available in the technical table reported under each of the PMS data elements and classes.

2.8. Is PMS designed to store only Authorised Medicinal Products (AMP) or also for Investigational Medicinal Products (IMP)?

At the moment, PMS is only storing AMPs.

PMS is an ISO IDMP compatible database. ISO IDMP standards are developed to cover both Investigational and Authorised Medicinal Products; thus, PMS could be developed to also contain IMPs.

On this aspect, the Agency is currently debating the most suitable technical solution to store IMPs and whether PMS has the right capabilities to cover this task. This matter falls within the ongoing business strategy update, particularly concerning investigational medicinal products.

2.9. Will the Pharmaceutical Product Identifier (PhPID) be integrated in PMS?

For the moment the PhPID is not integrated in the PMS data model.

To move forward with the implementation of PhPID in Europe and support the generation of the Global PhPID, the Agency is focused on few key activities such as the data cleansing of substances. This activity is ongoing.

Moreover, to implement the ISO identifier globally, EMA is cooperating with international groups (i.e. WHO, FDA, and other global regulators) to pilot the implementation of such ISO identifiers worldwide. The Agency is therefore working at local level in Europe as well as at global level to identify a global solution.

In addition to the above the priority of the Agency is to focus in making available the PMS database and enable the users to access and enrich their authorised product data in PMS to enable the generation of the ISO Identifiers at Medicinal Product (MPID) and Packaged Medicinal Product levels (PCID) as well as PMS ID.

2.10. Where can I find the MPID assigned to my product and the PCID linked to my packaged medicinal product?

Please, take into account, that for the moment only the PMS ID has been generated as part of the initial migration of data to PMS and only the PMS ID is generated when inserting new products (either from SIAMED or from XEVMPD).

In order to create the MPIDs and PCIDs, and as stated in EU IG Chapter 2, there are some data elements needed such as devices in case the product is combined with one or the package components. This data is not yet captured in PMS and that is why the generation of these IDs is not possible for the moment.

Therefore, in case you need to identify a medicinal product, use the PMS ID. In case you need to identify a specific packaged medicinal product, you can use the technical package ID generated by the system and that can be found in the PMS API or in the Dynamic Reports in the Product UI (Package ID column).

2.11. The Data Carrier Identifier is a data element mentioned in the EU IG Chapter 2. Will PMS users be required to provide and maintain Global Trade Item Number (GTIN) in the PMS?

Yes, the Agency is enabling companies to provide the product data carrier identifier, such as GTIN codes from barcodes, into PMS. As stated in [EU IG Chapter 2](#), the provision of such information is optional. Nevertheless, users shall be aware that the provision of this data type will support use cases such as the easy access to patient information thorough the scanning of the data carrier identifiers as well as use cases on the matter of the supply chain and sales. Users are therefore recommended to provide such data in PMS as this will create efficiencies for patients.

From Q3-Q4 2025, the Product UI will allow the submission and maintenance of this field for non-CAP products. The submission and maintenance of this field for CAPs will be handled, for the moment, via Service Desk.

2.12. How can product data from PMS be exported and in which formats?

Users can export authorised product data from PMS through:

- **PMS PUI:** product data can be exported in **XML format** upon acceptance of the Data Protection Disclaimer from each of the product PUI pages. Alternatively, consolidated product data can be exported in **excel file** from the private Dynamic Product Report focused on specific elements such as the full list of authorised products, manufacturers, ingredients, pack sizes, ATC codes etc.

In PMS PUI, a single report, consolidating all product-related information is not available due to the large amount of data available in PMS. Additional Dynamic Product Report types will be delivered based on specific use cases.

- **PMS API:** full products dataset can be exported in **JSON, XML, HTML, Text, Auto formats**. The export is product-based.

2.13. Free text fields coming from XEVMPD show the information in capital letters, why?

After any submission to XEVMPD, the system is converting the text to capital letters. This is the way XEVMPD captures the data for free text fields and therefore, as PMS is consuming from XEVMPD, it will also show these fields with capital letters. This is the case of the name parts or the package description.

2.14. In PMS there are different sections for ingredients. Where is this data coming from?

[EU IG Chapter 7](#) states that ingredients can come from either SIAMED or XEVMPD, depending on the section. The ingredients for the manufactured item are sourced from SIAMED, meaning that this section will only be filled for CAPs. In contrast, ingredients in the pharmaceutical product section are sourced from XEVMPD.

The medicinal product section displays both the ingredients from the manufactured item and the pharmaceutical product. However, it's important to note that in some cases, SIAMED may capture the salt or hydrate of an active substance instead of the active moiety, while XEVMPD may capture the active moiety. When this occurs, both active ingredients will be displayed in the medicinal product section, while each form of the active substance will be referred to in the manufactured item and pharmaceutical product sections separately.

2.15. I have submitted an update to XEVMPD and a new PMS ID has been generated in PMS for my product. Why is this happening?

[EU IG Chapter 9](#) explains that updates to grouping elements in XEVMPD will result in the generation of new PMS IDs. This means that any changes made to the authorized dose form, full presentation name, active substance or its strength, among others, would generate a new PMS ID since the defining elements of a PMS medicinal product have changed.

It's important for MAHs to be aware of this process so that they can take it into consideration when making updates to their products in XEVMPD. Ensuring that accurate and up-to-date information is maintained in XEVMPD can help to minimize the number of new PMS IDs generated and reduce the potential for confusion or errors.

2.16. Different EV Codes have been migrated under the same medicinal product in PMS. Nevertheless, they should not be grouped as they are considered different marketing authorisation even though all the data in XEVMPD is the same. They are just duplicate marketing authorisations. How can I split the products in PMS?

As explained in EU IG Chapter 7 and 9, EV codes from XEVMPD are merged under the same medicinal product when the grouping elements shared the same information. Depending on the authorisation country, the grouping elements might change. In order to split the products in PMS for EV Codes that have the same information, small changes should be performed to any of the grouping elements in XEVMPD.

For example, spaces in the name can be included to one of the EV Codes so the system recognise these two EV Codes as different and two different medicinal products are created in PMS. Please, include the spaces in the middle of the name and not at the end, as spaces at the end are not considered. For example: ibuprofen 50 mg tablets could be changed to ibuprofen 50 mg tablets (two spaces between ibuprofen and 50).

3. Product User Interface (PUI)

3.1. How often the product data between XEVMPD and PMS PUI is synchronised?

In principle, the update of data in PMS following XEVMPD submissions is almost simultaneous.

Nevertheless, from the PMS API to the Product UI, the process takes some time as the integration routine runs for all the records we have in PMS. The Agency is working on the improvement of the performance as for the moment, updates performed in XEVMPD might take a couple of hours to be reflected in the Product UI.

3.2. Are Product EV Codes (PRD) made available PMS PUI?

Yes. When accessing PMS PUI, in each PMS product entity there is a data field called "EV code". This attribute is available in the main page named "Medicinal Product" and it contains the full list of EV code(s) linked to the relevant product. Moreover, in the packaged medicinal product section, users can see to which pack size, each EV code is linked to.

EV Codes can also be found in some of the Dynamic Reports that are available in the Product UI.

In case of non-CAP, the EV code(s) reported in PMS are the result of the data synch from XEVMPD to PMS. In case of CAP, the EV code(s) reported are the result of the match and merge protocol run between SIAMED and XEVMPD as explained in [EU IG Chapter 7](#).

3.3. A medicinal product or packaged medicinal product does not have an EV code associated. What is happening?

Non-CAP products are migrated only from XEVMPD so any packaged medicinal product created in PMS should have an EV code associated to it and therefore they should also appear in the Product UI at the level of the medicinal product.

In the case of CAPs, as explained in [EU IG Chapter 7](#) and [EU IG Chapter 9](#), CAPs are generated first from SIAMED and once the record is created in XEVMPD, the match and merge protocol links the presentation from SIAMED with the EV Code from XEVMPD.

If any of the packaged medicinal product for a CAP does not show an EV Code linked, it is because the match and merge has not worked and this could be due to different reasons.

Please, make sure first of all that the EV code for this specific presentation has been submitted to XEVMPD. The authorisation country should be EU.

Please, make sure that the MAH Org EV code is mapped to the same LOC ID that the product is referring in PMS (and coming from SIAMED). The match and merge protocol relies on the LOC ID from SIAMED and the ORG EV Code from XEVMPD. If the mapping is not present in OMS, it will not work.

Please, make sure that the Authorisation number and EU Number in XEVMPD are the same as the authorisation number from SIAMED.

If everything is correct but the match and merge has not happened, you can submit a dummy update to this record in XEVMPD (by including a dot in the package description for example). Wait to check if the EV Code is linked to your presentation. If that does not work, please, raise a ticket in Service Now.

3.4. Why some PMS data elements are empty and what is the impact of this?

At the moment of the PMS Go-Live, some product data were missing. This is because authorised product data are loaded from two sources: SIAMED (EMA internal product management database) and XEVMPD (the product database in line with Article 57(2), second subparagraph of Regulation (EC) No 726/2004 accessible by external users) storing CAPs and non-CAPs data.

XEVMPD and SIAMED's data models are smaller than the PMS one. While XEVMPD contains around 50 attributes, PMS has around 180 data elements. Thus, as result of the product data load, several data elements are empty (i.e. packaging material, manufacturing business operations, etc).

On this regard, the Agency is focusing on enabling the product data enrichment process on a step-based approach. As a matter of priority and as communicated in the past [webinars](#), in order to support [ESMP](#) implementation, in 2025 users will be allowed to submit manufacturers of non-CAPs in PMS and gradually allow the product data enrichment of additional fields to support PMS and other projects. Please check the [ESMP web page](#) for further information on this platform.

3.5. In PMS PUI the Marketing status and marketing status dates are visible. From which system does this information come from?

At the moment, this information is not available in PMS API as neither XEVMPD nor SIAMED stores it.

Maintenance of this data is done in IRIS for Centrally Authorised Products and the Product UI is taking this information from there. The Agency is internally discussing how this information will be managed in the future: whether in IRIS or directly in PMS. As stated before, for CAP products, the marketing status is managed in IRIS while for non-CAPs, marketing status data is managed in [ESMP](#), both systems requiring the use of a specific template.

The Agency will communicate in due time any update on this matter.

Please, take also into account that the marketing status information that is shown in the Product UI is not completely aligned with the data captured in IRIS. The PMS team is working to solve this issue, so please, for the moment, do not consume this data from the Product UI but only from IRIS.

3.6. Will the Marketing status captured in IRIS be synced with PMS PUI in real-time?

Currently, marketing status for CAPs is managed in IRIS and is not stored in PMS. This process will remain unchanged. For NAPs, data on marketing status must be submitted using templates provided by [ESMP](#). However, PMS is not synchronised with this data set.

There will be future discussions about possibly integrating this data into PMS since it exists in the data model. However, for now, the process remains with IRIS and ESMP by using specific templates.

Additionally, for non-CAPs, data on marketing status will only be requested during crises or MSSG-led preparedness exercises, such as monitoring specific product groups like antibiotics.

3.7. Is there a way to export all product data?

There are two ways to export product data.

Users connecting to the PMS API can download all the data for products under their organisation.

If the user has no access to the PMS API, then, some data can be downloaded through the Dynamic Reports from the Product UI. The PMS team has deployed different reports that can be used by users to download, in Excel or CSV format some data such as a list of products, list of pack sizes, products based on ATC Codes, list of manufacturers, etc.

Please, take into account that for the moment there is no way to download all the data for all the products in an Excel or CSV file.

The Agency will work on the improvement of these Dynamic Reports.

3.8. Will centrally authorised products with authorisation country NO, IS and LI disappear from the Product UI?

Yes. To support other processes such as inspections, marketing status, or eAF, we have decided to remove existing records where the authorization procedure is 'centrally authorized procedure' and the country of authorization is different from EU by December 2024. While these products must still be submitted to XEVMPD following business requirements, they are no longer required in downstream systems, and only the EU record is needed.

As a result, EMA has decided to remove these records from the PLM Portal. During Q1 2025, the PMS team will work to block the generation of these products in PMS even if they are submitted to XEVMPD. It's important to note that XEVMPD rules still apply, meaning that these records must be submitted and maintained in the Art. 57 database, even though they will not be migrated to PMS.

3.9. Why some medicinal products don't have an MA number?

Please, take into account that, as explained in EU IG Chapter 2, MA numbers can be captured at two levels: medicinal product and packaged medicinal product.

In the same chapter it is explained that, only if all packages have the same MA number, then this will appear in the medicinal product.

Therefore, if your medicinal product is composed by different pack sizes with different MA numbers, the MA number at medicinal product will be empty and you can find them at package level. Only when all the packages have the same MA number, then, it will also be captured at medicinal product level.

3.10. The MedDRA version of XEVMPD and the Product UI don't match. Why?

In XEVMPD, when submitting the MedDRA codes, the latest version of MedDRA should be selected. These MedDRA codes are mapped to the RMS list and shown in the Product UI. In the Product UI, the version linked to each MedDRA codes comes from the attributes of each term and the version is linked to the latest version of MedDRA when the term changed. Therefore, if the same term has not changed since version 21.1 of the MedDRA list, that is the version that will appear in the Product UI even if in XEVMPD we have indicated version 27. There is no need to raise a ticket for this as it is not considered an issue.

3.11. During the enrichment process, who has access to the different change requests created?

For the moment, everybody from a specific organisation can view the change requests created for the products of that organisation. Nevertheless, only the owner of the change request can view the changes, edit the change request and submit it. EMA is working to implement a feature by the end of Q1 2025 so any user from the organisation can have access to all the change requests, can edit them and submit them (only for the change requests with status draft and modified).

4. Known issues in PMS

4.1. After reviewing my products in the PMS API or the Product UI I have found several issues with my data. What should I do in order to correct it?

Please, take into account that, **depending on the type of error, different actions might be needed from the MAH:**

1. If the **issue is coming from XEVMPD**, then, the solution might be needed in XEVMPD and the user might need to submit an update there.
2. On the other hand, if the **issue is found on data coming from SIAMED**, then, the MAH should **open a ticket in Service Desk** requesting the change there. Please, review [EU IG Chapter 7](#) and [EU IG Chapter 9](#) to understand how the data is migrated from the different sources and make sure where the correction is needed.
3. Moreover, in this section you can find issues that are already known and for which the resolution has been prioritised. **Please, do not open tickets if you find any of these issues in your products.** *The PMS team will communicate as soon as these issues are solved so MAHs can check their products again.*

List of known issues:

Issue	Description	Expected resolution date	Action for MAHs
Missing names in multilingual products	Some names were missing in multilingual products even though they were submitted to XEVMPD.	Dec-24	Submit an update to XEVMPD so the system can capture the missing name
Products from Luxembourg	During the initial migration a wrong business rule was implemented (the MA number was used as a grouping element). Now the same approach as the one used for Belgium products is followed so the correct grouping criteria is applied to the products from Luxembourg.	Dec-24	Review products from Luxembourg. If grouping of EV Codes is not correct, raise a Service Now ticket.
2-ISO letter codes wrongly displayed in the UI	In the Product UI, in the left filtering menu, the wrong 2-ISO letter codes are wrongly displayed for Estonia (EW), Liechtenstein (FL) and Finland (SF).	Dec-24	None
Nullified medicinal products	Nullified medicinal products and packages were available in the Product UI. Now they can't be seen in the product UI but they are still available in the PMS API.	Dec-24	None
Units of measurement 'each' was not mapped to any term in RMS	When in XEVMPD the strength of the active substance was submitted as per '1 single each', this term was not mapped to RMS and therefore the denominator is missing in PMS and the Product UI. The RMS team has created now the term 'item' in the units of measurement RMS list and the mapping has been created.	Q4 2024	If your product is impacted by this case, you can send a dummy update in XEVMPD to force the system to take this new mapping.
Marketing status data for CAPs	This section contained information coming from IRIS. This section is no longer available in PMS UI.	Q2 2025	None
Cyrillic characters showing '?' in the full presentation name	This is not an issue but a reflection of the data captured in XEVMPD. Please, remember that messages with special characters must be sent from XHTML view to avoid adding question marks characters instead of Greek or Cyrillic characters.	Not an issue	If XEVMPD already contains question marks, then, a new product version must be sent (using XHTML view)
Full product name for products authorised in Greece	In the Product UI, in the medicinal product page, the name for Greek products is not display. This is due to a miss mapping with RMS language value leading to the unavailability of the name in this section.	Q3 2025	None
Missing Regulator in the	This is due to the missing LOC ID in the PMS API.	Q3 2025	None

Issue	Description	Expected resolution date	Action for MAHs
Product UI			
Missing authorised dose form in Product UI	Some products in the PMS API have captured the authorised dose form as the EV Code instead of as the RMS ID. If this is the case, the authorised dose form is missing in the product UI.	Q3 2025	None
Wrong EV code linked to a packaged medicinal product.	In the Product UI, each packaged medicinal product is linked to an EV Code coming from XEVMPD. Nevertheless, when there has been a transfer, the previous EV Code is still captured and the new EV Code is not shown. In the PMS API, both EV codes are linked to this packaged medicinal product and updates to the new record will be captured in PMS. EMA will implement a solution so the latest EV Code is shown instead of the old one. Additionally, a new process for transfer of MAH for NAPs will be implemented and described in Chapter 9 of the EU IG.	Q3 2025	None
Packaged medicinal products transferred in XEVMPD.	If in XEVMPD, users have submitted multiple EV Codes making reference to the same previous EV Code (because former MAH has only one EV code for multiple pack sizes and new MAH has split and submit multiple EV Codes, for example), only one packaged medicinal product is available in PMS. EMA will create the missing packaged medicinal products that are not available in PMS after the transfer	Q3 2025	None
Unit of presentation field in the pharmaceutical product is missing	In some products, the units of presentation of the pharmaceutical product are missing.	Q3 2025	None
Comparator field is missing	In some products, the comparator from XEVMPD is missing (terms such as 'equal' or 'more than').	Q3 2025	None
Units of measurement or presentation in the strength are missing	In some products, the units of measurement or presentation in the strength are missing.	Q3 2025	None
Valid - pending products are shown as surrendered in the Product UI	This is due to an issue with the mapping between XEVMPD and RMS.	Q3 2025	None
Range of strengths are missing in the Product UI	If in XEVMPD, the strength of the ingredient is captured as a range, only the numerator is captured.	Q3 2025	None
MA number is captured at product level even if there	In some cases one MA number is still captured at product level even if there are different MA numbers at package level.	Q3 2025	None

Issue	Description	Expected resolution date	Action for MAHs
are different MA numbers at pack level			
Some updates submitted to XEVMPD are not reflected in PMS	This issue is coming from XEVMPD and the reason is that XEVMPD was sending an old version of the product to PMS. That is why the changes were not reflected in PMS.	Q3 2025	Try to send XEVPRMs with different values in the message number to avoid this issue.
Dates coming from SIAMED	Some dates coming from SIAMED such as the EBD or procedure start date/end date are not correct.	Q3-Q4 2025	None
End date of manufacturing business operations	End date for manufacturing business operations from SIAMED (CAPs) is not captured. EMA is working to include this information in the deleted MBOs	Q4 2025 - 2026	None
Duplicated or triplicated packages	Products authorised in multilingual countries have as many packages as EV Codes submitted to XEVMPD. Therefore, the same package is captured in different languages. EMA is discussing how to merge these pack sizes.	Q4 2025 - 2026	None
Duplicated entries	In some specific cases, there might be some duplicated entities in some CAP medicinal products such as: <ul style="list-style-type: none"> • Indications • ATC Codes • Ingredients • Pharmaceutical product • Route of administration • Packaged medicinal product. EMA is working to improve the integration between SIAMED and PMS to avoid the generation of these duplicates. 	2026	None
Truncated full product names	There is a technical limitation of the Product UI and long product names might appear truncated. The full name is captured in PMS but due to the technical limitation not fully visible in the Product UI.	Unknown	None
Missing QPPV contact and Pharmacovigilance enquiry information data	QPPV code and the Pharmacovigilance enquiry information has been migrated to PMS but it is not shown in the Product UI	Unknown	None
Attached document(s) section	Documents are not maintained in PMS API or in the Product UI for the moment.	Unknown	Do not review this section.

Issue	Description	Expected resolution date	Action for MAHs
Incorrect organization names displayed in the Product UI	If an organization has undergone changes in OMS due to updates in their name, it's possible that the old name may still appear in the Product UI.	Unknown	If the issue is blocking any regulatory procedure, raise a ticket in Service Now.
Access to products might not be possible if merges or acquisitions have been performed in OMS	In some cases, when an organisation has undergone a merge in OMS, even if the mapping between the LOC ID and the ORG EV Code is correct, products might have been allocated to the old ORG ID and therefore the products can't be accessible as the role in IAM is granted to the other ORG ID.	Unknown	Access can be requested to historical records in IAM. Please check this IAM info page .

4.2 Taking into account the known issues, how should I manage the verification of data in PMS?

First of all, it is important to understand that some of the known issues are not affecting all products in PMS. That means that not all products have duplicated pharmaceutical products, or the name is truncated.

We also understand that, for Product UI users, revision of some specific data might be difficult as there is no way to export it for all their products at the same time (i.e. there is no way, for the moment, to download all indications in an excel or CSV format).

If the user has access to the PMS API, then, the recommendation is to review as many data as possible to make sure that the migration from SIAMED and/or XEVMPD was performed correctly.

For the Product UI users, the revision might be a bit limited, but there are still some checks they can perform.

Among these checks, users should make sure that all their products have been migrated from SIAMED/XEVMPD and whenever applicable, the correct packaged medicinal products have been migrated under the correct medicinal product. Also, make sure that new records submitted to XEVMPD are migrated correctly.

Users should also check that specific terms coming from the source and mapped to RMS, reflect the correct term (e.g. authorised pharmaceutical dose form, ATC codes, MedDRA Codes, legal status of supply, etc.)

Users can also check that ingredients coming from XEVMPD are reflected correctly and the correct mapping between XEVMPD and SMS is reflected.

5. Submission of data to support ESMP.

5.1. What is the deadline for the enrichment of data in PMS?

As communicated at the [PMS Info Day](#) hosted on 16 April 2024 and [European Shortages Monitoring Platform Essentials and Industry Reporting Requirements](#) hosted on 24 June 2024, MAHs should submit pack sizes of medicinal products listed under the Union List of Critical Medicines (ULCM) as well as structured data on pack sizes. Moreover, manufacturers and manufacturing business operations are also in the scope of this enrichment. The Agency recommends MAHs reviewing the ULCM list to identify the affected products. This list is based on ATC codes, so they can identify if some products of their portfolio are affected or not. As result of the ULCM review, impacted MAHs should submit via XEVMPD the authorized pack sizes for the affected products so the relevant product entities can be reflected in PMS. The **deadline for this activity is 1 February 2025**.

On the other hand, structured pack size data, manufacturers and manufacturing business operations should be submitted (for non-CAPs) directly to PMS. From Q1 2025, the enrichment capability in the Product UI and in the PMS API will be released and additional information will be shared. The deadline for the submission of this information for those products under the ULCM is **December 2025**.

5.2. Is it possible for PMS PUI users to create pack sizes directly in the PUI or the PMS API instead of in XEVMPD?

No. Currently, the only way to submit product data to PMS is through XEVMPD. Medicinal product entities shall be created in XEVMPD as per regulatory requirements outlined in Article 57 legislation.

Upon submission of product data in XEVMPD the relevant medicinal product entity will be loaded and generated in PMS.

For further details on how to submit pack sizes through XEVMPD to PMS, please refer to the hosted [Public webinar on pack size submissions: from XEVMPD to product management service \(PMS\)](#) (11 July 2024).

All the information on how to submit additional pack sizes through XEVMPD can be found in the [Public webinar on pack size submissions: from XEVMPD to product management service \(PMS\)](#) (11 July 2024) and also in [Chapter 3.II of XEVMPD](#).

5.3. What information should be included in the package description in XEVMPD?

As stated in [Chapter 3.II](#) of XEVMPD, the package description field is more important and therefore some more meaningful information should be provided. For those products, where the authorisation number is the same for all pack sizes, national IDs should also be provided in the package description. Other information such as the pack size (quantity and units of presentation) or the material can be provided either on the national language or in English.

During the [Public webinar on pack size submissions: from XEVMPD to product management service \(PMS\)](#) additional information on the national IDs was also shared, but an updated table can be found here. Please, take into account that it is the MAH's responsibility to know how the non-CAP products were authorised by the national competent authority and the national code assigned to each pack size. MAHs can contact the NCA in case they need additional information.

Please, consider that for medicinal products authorised in countries with more than one official language (i.e. Belgium, Liechtenstein and Finland), the package description in the XEVMPD records that belong to the same pack size, should be the same (same information in the same language). This will allow the PMS team to merge those EV codes under the same packaged medicinal product. This requirement is also reflected in the package description section of [Chapter 3.II of XEVMPD](#).

Country	MA number level	National ID at pack
Austria	MP level	Packungsnummer (internal), Pharmazentralnummer for marketed packages (PIP code)
Belgium	between medicinal product level and packaging level	CTI Extended
Bulgaria	MP level	
Croatia	Both	Yes.
Cyprus	MP level	only internal
Czech Republic	MP level	yes: SUKL code.
Denmark	MP level	
Estonia	MP level	Yes. There is a national package code generated by our internal database. Package code
EU	Pack size	Ø
Finland	MP level	Yes
France	Both	The package number (CIP with 13 characters) from the SmPC should be used as MA number.
Germany	MP level	nationale Packungs-ID
Greece	MP level	
Hungary	Pack size	
Iceland	MP level	Yes. Nordic article number and GTIN/NTIN but only for marketed packages

Ireland	MP level	No
Italy	Pack size	Ø
Latvia	MP level	"Product ID" (in LV: Produkta ID).
Liechtenstein		
Lithuania	Pack size	Ø
Luxemburg	MP level	Yes. "Numero national" or national number (7 digits)
Malta	MP level	No additional identifier is given for each pack
Northern Ireland		
Norway	MP level	Yes. Nordic article number and GTIN/NTIN but only for marketed packages
Poland	MP level	
Portugal	MP level	Name in PT "Número de registo" (registration number).
Romania	Pack size	Ø
Slovakia	MP level	"ŠÚKL kód" (ŠÚKL code (SIDC code))
Slovenia	Pack size	Ø
Spain	MP level	Codigo nacional
Sweden	MP level	Yes. NPL pack id
The Netherlands	MP level	No

5.4. Does the content of the PMS package description match with the XEVMPD package description?

As stated in [EU IG Chapter 7](#) the data reported in the PMS field for package description is migrated from SIAMED (EMA internal database) for CAPs and from XEVMPD for non-CAPs. Thus, the PMS package description will match with the data submitted in XEVMPD for non-CAPs.

5.5. The user is requested to specify the pack size of authorised medicinal products in the package description field available in XEVMPD. Will the free text reported in XEVMPD be transformed in structured data in PMS?

No. The information submitted in the package description field in XEVMPD will be migrated to the packaged description field of the packaged medicinal product in PMS.

Please, review [Chapter 3.II of XEVMPD](#) to understand how the package description should be submitted in XEVMPD so we have meaningful information in PMS.

The structured data on pack sizes (pack size field in PMS) is composed by a numeric value and a unit (e.g. 28 tablet). For CAPs, this data is captured from SIAMED but for Non-CAPs, this field is empty. To structure the pack size data, users should submit an update to PMS. This update will fall under the PMS enrichment process which will be available from Q1 2025.

5.6. Do I need to submit all authorised pack sizes for all my products, or shall I do it only for those products that fall under the ULCM (Union List of Critical Medicines)?

Please, take into account that it depends on the type of product and how the authorisation has been granted by the National Competent Authority.

At the end of [Chapter 3.II of XEVMPD](#) you have a diagram explaining which information you need to submit depending on which type of product we are referring to.

5.7. When submitting the manufacturers and manufacturing business operations as part of the enrichment process, which manufacturers should be included?

As explained during the [Submission of Manufacturers, Manufacturing Business Operations \(MBOs\) and structured pack size data to Product Management Service \(PMS\) | European Medicines Agency \(EMA\)](#) webinar, only those manufacturers and manufacturing business operations that are submitted with the eAF should be reported, for the moment, to PMS.

Please, refer to this webinar and to EU IG Chapter 3 for additional information.

5.8. Manufacturing business operation for CAPs are not captured as in the eAF. Why?

The RMS list for manufacturing activity is a hierarchical list. While in the eAF, whenever available, the RMS terms of the second level are submitted, SIAMED is only capturing the first level. For example, while in the eAF, the selected term for a manufacturer of the medicinal product can be Chemical / Physical testing (second level term), in SIAMED, only Quality control testing of medicinal product is captured.

MAHs are not required to raise any ticket in those cases, as it is accepted by ESMP to capture the data like this for CAPs.

EMA will be discussing if in the future there is a need to enrich this data or make any changes, but for the moment, for CAPs, this data is correct.

For non-CAPs, as explained in EU IG Chapter 3, the same values as in the eAF should be captured.

5.9. When inserting a new pack size in XEVMPD, instead of a new packaged medicinal product, a new medicinal product is created in PMS. Why is this happening?

As described in [EU IG Chapter 7](#) and [EU IG Chapter 9](#), there are some data elements from XEVMPD that are used to group EV codes under the same medicinal product. If a record from XEVMPD that is supposed to belong to a specific medicinal product contains different data in one of these fields, it will not be merged correctly.

The PMS team recommends checking the data from the other EV codes to make sure it is correct and the same as the one that is going to be submitted with the new EV code. Take into account that legacy records in XEVMPD might have been validated and some changes performed by the XEVMPD validation team.

Take also into account that any change performed during the lifecycle of the record might impact the structure of the product in PMS if any of those grouping elements is changed. Please, review [EU IG Chapter 7](#) and [EU IG Chapter 9](#) for additional information.

6. PMS and the web-based electronic Application Form (eAF)

6.1. eAF retrieves authorised product data from PMS. What is the impact on the use of eAF when products data are not up-to-date in XEVMPD?

As stated in the [Legal notice on the implementation of Article 57\(2\) of Regulation \(EC\) No. 726/2004](#) marketing authorisation holders (MAH) are required to electronically submit authorised product data and maintain product data up-to-date in XEVMPD according to the established timelines. Shall the MAH not be compliant with the legal obligations, it will be deemed as failing to meet its responsibilities.

Non-compliance with the legal obligation in XEVMPD triggers:

- **Inability to use the eAF:** eAF is re-using PMS data loaded from XEVMPD and SIAMED. Shall the MAH's product is not submitted in XEVMPD and/or maintained updated, the eAF cannot be used as data will not be loaded into the relevant systems.

- **Potential rejections:** If the product data is incorrect, the submitted eAF may be rejected by NCAs based on the incorrect information reported.
- **No structured changes:** With the upcoming structured changes in the eAF, it is crucial for MAHs to keep product data information up to date in the systems.
- **Inspections and reviews:** The Agency monitors the quality of the product data in XEVMPD. In case of identified discrepancies these are reported to NCAs' inspectors who will contact the relevant MAH.

To prevent any of the above-mentioned issues, the Agency recommend the MAH to ensure that the authorised product data is consistently updated and accurately reported in XEVMPD so these can be loaded across the relevant systems and application.

6.2. I want to use the web-based eAF for products that are not in scope of XEVMPD, such as herbal or homeopathic products. What shall I do?

eAF is consuming data from PMS, and, at the same time, PMS is fed by XEVMPD. Therefore, any product that is needed in eAF should be submitted to XEVMPD.

XEVMPD already allows the submission of these type of products, so please, review [Chapter 3.II of XEVMPD](#) to understand how to submit these products. Once submitted, they will be available in the PLM portal (Product UI and eAF).

6.3. For MRPs and DCPs, after a medicinal product is authorised in the Referenced Member State but while it is under the national phase on the Concerned Member States, a variation might need to be submitted. How and by when these pending products can be submitted to XEVMPD so they appear in the PLM Portal?

A new authorisation status is available in XEVMPD for the submission of these products to XEVMPD. Chapter 3.II of XEVMPD has being updated to explain how to submit and maintained these records.

Please, take into account that this use case only applies to MPRs and DCPs. Pending pure NAPs can't be submitted to XEVMPD as no variations can be submitted to pending pure national products. Only once the national product is authorised, a variation can be submitted.

This authorisation status is to be used only when the medicinal product has been newly authorised by the Reference Member State but is under evaluation in the Concerned Member States. The authorisation status in the RMS should be Valid (1) and Valid – pending national phase (12) in the CMS(s).

This authorisation status should be used when the medicinal product has not been authorised yet by the CMSs. Once the product is authorised in CMS(s), the authorisation status should be updated to Valid. This status SHALL NOT be used when a variation is being evaluated by the CMSs once they have already authorised the initial MAA of the product.

For the pending medicinal products, some data might not be available as it is to be approved by the CMS(s). Therefore, this is the information that should be reflected until the product is authorised and an update is submitted to XEVMPD to provide the correct information:

- Use EU other approval/authorisation procedure (13) so these EV Codes are not considered in the fee calculations

- Authorisation number: 'Not assigned' (unless it is already known, in which case, it can be provided)
- Authorisation date: same as the one provided for the RMS and to be updated once authorised in the CMSs
- Full presentation name: the proposed name can be included in the local language and to be updated once authorised
- For the rest of the fields, the same data as the one provided in the RMS (e.g. Indications, ATC codes, composition, etc)

7. Guidance & Support

7.1. How shall any identified PMS related data quality issue or questions be reported?

Users can find the relevant instructions in the [Product User Interface \(PUI\)](#) training and [PMS API training sessions](#) where **guidance to users through troubleshooting scenarios** is provided. e.g. product search challenges and how to send a Service Desk request if issues persist.

Depending on the type of issue encountered by the marketing authorisation holders, different solution might apply.

For **general** or **technical support** with the **PMS**, please report an EMA Service Desk request.

- [Report an issue with the PMS](#), to create a ticket for the issue you are experiencing with PMS API;
- [Request information about the PMS](#), to create a ticket for the question you may have on PMS in general or PMS API. To ensure that the ticket reaches the most appropriate team, users are recommended to select "Service: SPOR" and "Service Offering: PMS".
- [Request SPOR API Services](#), to request support on specific SPOR API services and accesses. To ensure that the ticket reaches the most appropriate team, users are recommended to select "SPOR API request type: PMS" and "Environment: PMS - API PROD".

For **technical support** with the **PLM Portal**, please use directly the [PLM Portal-PUI section of the EMA Service Desk portal](#). This includes issues related to creation of new accounts, access to existing accounts, accessing data and performance of PMS PUI portal.

If you have a user account for a system hosted by EMA, you should use the same username and password for this service. Otherwise, please [Sign up for a new account or reset your login credentials](#).

The Service Desk portal is optimised for use with Chrome, Edge, Firefox or Safari web browsers. If you encounter problems, please use one of these browsers instead.

- [Report an issue with the PLM Portal](#) – PMS PUI, to create a ticket for the issue you are experiencing;
- [Request information about the PLM Portal](#) – PMS PUI, to create a ticket for the question you may have.

Depending on the issue or question, you can select from different **problem areas**:

- PLM portal – PMS PUI General (topics covering multiple aspects and/or general nature)

- PLM portal – PMS Product Data (issues and questions with the product data as exposed/published in PUI)
- PLM portal – PMS PUI access (issues and questions on the access to PUI)
- PLM portal – PMS PUI functionalities (issues/discrepancies/errors with capabilities i.e. filtering, exporting, sorting, searching etc.)

Please provide a clear description of the issue and provide screenshots or any supporting document as attachment as these can help to solve the query faster.

7.2. Where are all PMS guidance documents stored?

All PMS guidance documents are available on the dedicated [PMS Guidance documents page](#) within the PLM Portal. This page includes links to the following resources:

- **User Guides:** Access all chapters of the EU Implementation Guide, the onboarding document for SPOR users, and PUI user guides.
- **Training Session Materials:** Find links to event web pages for relevant training sessions, including presentations and recordings.

7.3. Where can users find regular news on PMS work?

The [PMS news page](#) on the PLM Portal is regularly updated with the latest information on PMS, including development announcements and event promotions. Please visit the page frequently to stay informed about the latest updates.

Additionally, stakeholders interested in PMS can [subscribe](#) to the PLM Insights Newsletter, which is distributed quarterly.